Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Phasebio Pharmaceuticals Inc
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Phasebio Pharmaceuticals Inc since year 2005.
Table 2 shows the detailed insider transactions of Phasebio Pharmaceuticals Inc since 2005.
The reporting company's ticker symbol is PHAS. The reporting company's CIK number is 1169245.
The total value of stock buying since 2005 is $15,149,156.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2018-12-11||York Michael (VP, Corporate Development)||Buy||1,500||3.88||5,820|
|2018-12-10||Mow Jonathan P (Chief Executive Officer)||Buy||800||3.85||3,080|
|2018-12-07||Sharp John P (CFO and Secretary)||Buy||5,000||3.84||19,200|
|2018-12-07||Mow Jonathan P (Chief Executive Officer)||Buy||2,200||3.88||8,536|
|2018-12-04||Thorp Clay (Director)||Buy||4,000||3.13||12,520|
|2018-10-22||Crumpler John (10% Owner)||Buy||300,000||5.00||1,500,000|
|2018-10-22||Zeneca, Inc. (10% Owner)||Buy||600,000||5.00||3,000,000|
|2018-10-22||Thorp Clay (Director)||Buy||300,000||5.00||1,500,000|
|2018-10-22||Viswanathan Ravi (10% Owner)||Buy||1,800,000||5.00||9,000,000|
|2018-10-22||Tufts Linda (Director)||Buy||20,000||5.00||100,000|
Insider trading activities including stock purchases, stock sales, and option exercises of PHAS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Phasebio Pharmaceuticals Inc (symbol PHAS, CIK number 1169245) see the Securities and Exchange Commission (SEC) website.